Advanced search
Start date

IGFBP7 and dexamethasone resistance in acute lymphoblastic leukemia

Grant number: 17/03239-5
Support Opportunities:Scholarships in Brazil - Master
Effective date (Start): June 01, 2017
Effective date (End): February 28, 2019
Field of knowledge:Biological Sciences - Genetics - Human and Medical Genetics
Acordo de Cooperação: Coordination of Improvement of Higher Education Personnel (CAPES)
Principal Investigator:José Andrés Yunes
Grantee:Leonardo Luís Artico
Host Institution: Centro Infantil de Investigações Hematológicas Dr Domingos A Boldrini (CIB). Campinas , SP, Brazil


Acute Lymphoblastic Leukemia (ALL) is the leading cancer in children. Several studies show that the interactions between leukemic blasts and bone marrow stromal cells (OM) contribute to the resistance of ALL to chemo. In the previous work, we verified that leukemic cells secrete several proteins, among them IGFBP7, which together with their ligands (insulin, IGF-1 and IGF-2) stimulate MO cells to produce asparagine, creating a dynamic contrary to the action of L-asparaginase (chemotherapeutic drug used in the treatment of ALL). However, preliminary results lead us to believe that IGFBP7 may be acting in an autocrine and stromal independent manner, in promoting the resistance of ALL to chemotherapeutics. IGFBP7 was initially described as an adhesion factor, capable of interacting with components of the extracellular matrix. IGFBP7 was then interacted with integrins. Integrins participate in drug resistance in ALL, so that the activation of integrins may be one of the resistance mechanisms triggered by IGFBP7. Based on preliminary results, this project proposes to characterize the mechanism by which IGFBP7 promotes resistance to dexamethasone in leukemic cells. More specifically, it is intended to submit ALL cells to the presence or absence of IGFBP7, then: (1) identify altered gene sets, (2) check for activation of insulin signal transduction pathways / IGFs and integrins (AKT, ERK, IRS, FAK, src), (3) to assess nuclear translocation of the glucocorticoid receptor (GR), and (4) verify whether neutralization or silencing of B1 integrin interferes proliferation and resistance to dexamethasone IGFBP7-dependent. (AU)

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
CURY, NATHALIA MORENO; CAPITAO, REBECA MONIQUE; BORGES DE ALMEIDA, RENAN DO CANTO; ARTICO, LEONARDO LUIS; CORREA, JULIANA RONCHI; SIMAO DOS SANTOS, ERIC FRANCISCO; YUNES, JOSE ANDRES; DUARTE CORREIA, CARLOS ROQUE. Synthesis and evaluation of 2-carboxy indole derivatives as potent and selective anti-leukemic agents. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, v. 181, . (13/07600-3, 17/02400-7, 14/25770-6, 17/03239-5, 17/14737-6, 14/08247-8)
Academic Publications
(References retrieved automatically from State of São Paulo Research Institutions)
ARTICO, Leonardo Luís. IGFBP7 as a new therapeutic target in acute lymphoblastic leukemia. 2019. Master's Dissertation - Universidade Estadual de Campinas (UNICAMP). Instituto de Biologia Campinas, SP.

Please report errors in scientific publications list by writing to: